



**HAL**  
open science

## **Autism and developmental disability caused by KCNQ3 gain-of-function variants**

Tristan Sands, Francesco Miceli, Gaetan Lesca, Anita Beck, Lynette Sadleir, Daniel Arrington, Bitten Schönewolf-greulich, Sébastien Moutton, Anna Lauritano, Piera Nappi, et al.

### ► To cite this version:

Tristan Sands, Francesco Miceli, Gaetan Lesca, Anita Beck, Lynette Sadleir, et al.. Autism and developmental disability caused by KCNQ3 gain-of-function variants. *Annals of Neurology*, 2019, 10.1002/ana.25522 . hal-02151807

**HAL Id: hal-02151807**

**<https://hal.science/hal-02151807>**

Submitted on 22 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Autism and Developmental Disability Caused by *KCNQ3* Gain-of-Function Variants

Tristan T. Sands, MD, PhD<sup>1,2\*</sup> Francesco Miceli, PhD,<sup>3\*</sup> Gaetan Lesca, MD, PhD,<sup>4,5,6</sup>  
Anita E. Beck, MD, PhD,<sup>7,8</sup> Lynette G. Sadleir, MBChB, MD,<sup>9</sup> Daniel K. Arrington, MD,<sup>10</sup>  
Bitten Schönewolf-Greulich, MD,<sup>11,12</sup> Sébastien Moutton, MD,<sup>13</sup> Anna Lauritano, BS,<sup>3</sup>  
Piera Nappi, BS,<sup>3</sup> Maria Virginia Soldovieri, PhD,<sup>14</sup> Ingrid E. Scheffer, MBBS, PhD,<sup>15</sup>  
Heather C. Mefford, MD, PhD,<sup>7</sup> Nicholas Stong, PhD,<sup>2</sup> Erin L. Heinzen, PhD,<sup>2</sup>  
David B. Goldstein, PhD,<sup>2</sup> Ana Grijalvo Perez, MD,<sup>16</sup> Eric H. Kossoff, MD,<sup>17</sup>  
Amber Stocco, MD,<sup>18</sup> Jennifer A. Sullivan, MS, CGC,<sup>19</sup> Vandana Shashi, MD,<sup>19</sup>  
Benedicte Gerard, PharmD, PhD, CGC,<sup>20</sup> Christine Francannet, MD,<sup>21</sup>  
Anne-Marie Bisgaard, MD, PhD,<sup>11</sup> Zeynep Tümer, MD, PhD, DMSc,<sup>12,22</sup>  
Marjolaine Willems, MD,<sup>23</sup> François Rivier, MD, PhD,<sup>24</sup> Antonio Vitobello, PhD,<sup>25</sup>  
Kavita Thakkar, MD,<sup>26</sup> Deepa S. Rajan, MD,<sup>26</sup> A. James Barkovich, MD,<sup>27</sup>  
Sarah Weckhuysen, MD, PhD,<sup>28,29</sup> Edward C. Cooper, MD, PhD,<sup>30\*</sup>  
Maurizio Tagliatela, MD, PhD,<sup>3\*</sup> and M. Roberta Cilio, MD, PhD<sup>16,31\*</sup>

Address correspondence to Dr Cooper, Departments of Neurology, Neuroscience, and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, E-mail: ecc1@bcm.edu; Dr Tagliatela, Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II," Naples, Italy, E-mail: mtagliat@unina.it; or Dr Cilio, Departments of Pediatrics and Institute of Experimental and Clinical Research, University of Louvain, Brussels, Belgium, E-mail: roberta.cilio@uclouvain.be

\*T.T.S. and F.M. contributed equally. E.C.C., M.T., and M.R.C contributed equally.

From the <sup>1</sup>Department of Neurology, Columbia University Medical Center, New York, NY; <sup>2</sup>Institute for Genomic Medicine, Columbia University Medical Center, New York, NY; <sup>3</sup>Section of Pharmacology, Department of Neuroscience, University of Naples "Federico II," Naples, Italy; <sup>4</sup>Department of Medical Genetics, Reference Center for Developmental Anomalies, Civil Hospices of Lyon, Lyon, France; <sup>5</sup>French Institute of Health and Medical Research U1028, French National Center for Scientific Research UMR5292, Center for Research in Neuroscience in Lyon, Genetics of Neurodevelopment Team, Claude Bernard University Lyon 1, Lyon, France; <sup>6</sup>Claude Bernard University Lyon 1, Lyon, France; <sup>7</sup>Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA; <sup>8</sup>Seattle Children's Hospital, Seattle, WA; <sup>9</sup>Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand; <sup>10</sup>Children's Neurology, St Luke's Children's Hospital, Boise, ID; <sup>11</sup>Center for Rett Syndrome, Department of Pediatrics and Adolescent Medicine, National Hospital, Copenhagen, Denmark; <sup>12</sup>Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; <sup>13</sup>French Institute of Health and Medical Research U1231, Laboratory of Cognitive Neuroscience UMR1231, Genetics of Developmental Anomalies, Burgundy University, F-21000, Dijon, France; <sup>14</sup>Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy; <sup>15</sup>University of Melbourne, Austin Health, Royal Children's Hospital, Florey and Murdoch Institutes, Melbourne, Victoria, Australia; <sup>16</sup>Department of Neurology, University of California, San Francisco, San Francisco, CA; <sup>17</sup>Departments of Pediatrics and Neurology, Johns Hopkins School of Medicine, Baltimore, MD; <sup>18</sup>Pediatric Neurology, INTEGRIS Baptist Medical Center, Oklahoma City, OK; <sup>19</sup>Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, NC; <sup>20</sup>Molecular Genetic Unit, Strasbourg University Hospital, Strasbourg, France; <sup>21</sup>Genetics Department, Reference Center for Developmental Anomalies, Clermont-Ferrand University Hospital, Clermont-Ferrand, France; <sup>22</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; <sup>23</sup>Reference Center for Developmental Disorders, Department of Medical Genetics, Arnaud de Villeneuve Hospital, Montpellier University Hospital, Montpellier, France; <sup>24</sup>Department of Pediatric Neurology, University Hospital of Montpellier, and Physiology and Experimental Medicine of Heart and Muscle Unit, University of Montpellier, National Institute for Health and Medical Research, French National Center for Scientific Research, Montpellier, France; <sup>25</sup>Functional Unit 12, Innovation in Genomic Diagnosis of Rare Diseases, University Hospital Dijon-Bourgogne, Dijon, France; <sup>26</sup>Division of Neurology, Department of Pediatrics, Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA; <sup>27</sup>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA; <sup>28</sup>Neurogenetics Group, University of Antwerp, Antwerp, Belgium; <sup>29</sup>Neurology Department, University Hospital Antwerp, Antwerp, Belgium; <sup>30</sup>Departments of Neurology, Neuroscience, and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; and <sup>31</sup>Departments of Pediatrics and Institute of Experimental and Clinical Research, University of Louvain, Brussels, Belgium

**Objective:** Recent reports have described single individuals with neurodevelopmental disability (NDD) harboring heterozygous *KCNQ3* de novo variants (DNVs). We sought to assess whether pathogenic variants in *KCNQ3* cause NDD and to elucidate the associated phenotype and molecular mechanisms.

**Methods:** Patients with NDD and *KCNQ3* DNVs were identified through an international collaboration. Phenotypes were characterized by clinical assessment, review of charts, electroencephalographic (EEG) recordings, and parental interview. Functional consequences of variants were analyzed in vitro by patch-clamp recording.

**Results:** Eleven patients were assessed. They had recurrent heterozygous DNVs in *KCNQ3* affecting residues R230 (R230C, R230H, R230S) and R227 (R227Q). All patients exhibited global developmental delay within the first 2 years of life. Most (8/11, 73%) were nonverbal or had a few words only. All patients had autistic features, and autism spectrum disorder (ASD) was diagnosed in 5 of 11 (45%). EEGs performed before 10 years of age revealed frequent sleep-activated multifocal epileptiform discharges in 8 of 11 (73%). For 6 of 9 (67%) recorded between 1.5 and 6 years of age, spikes became near-continuous during sleep. Interestingly, most patients (9/11, 82%) did not have seizures, and no patient had seizures in the neonatal period. Voltage-clamp recordings of the mutant *KCNQ3* channels revealed gain-of-function (GoF) effects.

**Interpretation:** Specific GoF variants in *KCNQ3* cause NDD, ASD, and abundant sleep-activated spikes. This new phenotype contrasts both with self-limited neonatal epilepsy due to *KCNQ3* partial loss of function, and with the neonatal or infantile onset epileptic encephalopathies due to *KCNQ2* GoF.

*KCNQ2* and *KCNQ3* encode voltage-gated ion channel subunits mediating a subthreshold potassium current, called M-current ( $I_{KM}$ ), important in limiting neuronal excitability.<sup>1</sup> Missense loss-of-function (LoF) variants in *KCNQ3* cause benign familial neonatal epilepsy (BFNE), characterized by seizures in the neonatal period with normal development,<sup>2</sup> although rare families with more severe epilepsy phenotypes have also been described.<sup>3,4</sup> LoF variants in *KCNQ2* also cause BFNE, and de novo variants (DNVs) that result in more profound disruption of *KCNQ2* function (eg, through dominant negative effects)<sup>5</sup> lead to *KCNQ2* encephalopathy, a severe developmental and epileptic encephalopathy (DEE) characterized by seizures with onset in the neonatal period and global neurodevelopmental disability (NDD).<sup>6</sup>

Voltage-gated potassium channel subunits contain 6 transmembrane segments ( $S_1$ – $S_6$ ) and cytoplasmic N- and C-termini. Within the  $S_1$ – $S_4$  voltage-sensing domain (VSD), the  $S_4$  transmembrane segment includes a series of positively charged arginine residues that allows the channel to change its opening probability in response to changes in membrane potential.<sup>7</sup> Missense DNVs at the 2 outermost arginines of the *KCNQ3*  $S_4$  segment (R1: R227Q; R2: R230C/S) have surfaced in heterogeneous cohorts studied by exome sequencing for DEE, NDD, or intellectual disability (ID)<sup>8–10</sup> and cortical visual impairment.<sup>11</sup> Interestingly, DNVs in the corresponding residues in *KCNQ2* (R1: R198; R2: R201) were shown to result in gain of function (GoF)<sup>12</sup> with distinct DEE phenotypes. Patients with the *KCNQ2* R1 variant, R198Q, present in midinfancy with West syndrome, without preceding seizures in the neonatal period,<sup>13</sup> whereas patients with the *KCNQ2* R2 variants, R201C and R201H, present with neonatal onset encephalopathy without seizures and later develop infantile spasms.<sup>14</sup> The phenotypic spectrum associated with *KCNQ3* R227 and R230 variants has not yet been described.

Here, we delineate the novel electroclinical phenotype in 11 patients with 4 different heterozygous GoF DNVs at R227 and R230 in *KCNQ3*. In contrast to previously described patients with *KCNQ3* LoF, we found that these patients do not present with seizures in the neonatal period. Instead, within the first 2 years of life, they demonstrate global NDD and autism spectrum disorder (ASD) or autistic features. For 6 of 9 (67%) recorded between 1.5 and 6 years of age, spikes became near-continuous during sleep, raising concerns for epileptic encephalopathy. Sleep-activated spikes in 2 patients demonstrated a marked response to high-dose diazepam therapy, providing insight into a possible therapeutic intervention. Patch clamp analysis of each of the *KCNQ3* variants revealed GoF effects, including increased maximal current density and increased opening at membrane potentials where the channel would normally be inactive.

## Patients and Methods

### Patients

Patients with variants at R230 and R227 in *KCNQ3* were identified by epilepsy gene panel or exome sequencing in clinical and research settings. All sites received prior approval by their human research ethics committee when indicated, and parental informed consent was obtained for each subject. Groups were connected through the Rational Intervention for *KCNQ2/3* Epileptic Encephalopathy database ([www.rikee.org](http://www.rikee.org)), which is curated at Baylor College of Medicine under an institutional review board–approved research protocol.<sup>15</sup> One of the patients (Patient 6) was previously reported with minimal clinical details as part of an Epi4K epileptic encephalopathy cohort;<sup>16</sup> the others have not been previously reported. Pediatric epileptologists (T.T.S. and M.R.C.) reviewed the genetic test results and clinical reports, and evaluated the electroencephalographic (EEG) recordings, where

available. T.T.S., M.R.C., and E.C.C. communicated with treating physicians and/or parents of all patients. Patients were considered to have sleep-activated spikes if the abundance of spikes increased by more than twice that of the awake state. Near-continuous was defined as present for >70% of the sleep record.

### **Mutagenesis of KCNQ3 cDNA and Heterologous Expression**

Variants were introduced in *KCNQ3* human cDNA cloned into pcDNA3.1 by QuikChange site-directed mutagenesis (Agilent Technologies, Milan, Italy), as previously described.<sup>12</sup> Channel subunits were expressed in Chinese hamster ovary (CHO) cells by transient transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.<sup>17</sup> A plasmid encoding enhanced green fluorescent protein (Clontech Laboratories, Mountain View, CA) was used as a transfection marker; total cDNA in the transfection mixture was kept constant at 4 $\mu$ g.

### **Whole-Cell Electrophysiology**

Currents were recorded under whole-cell patch-clamp at room temperature (20–22°C) 1 to 2 days after transfection as reported.<sup>12</sup> Current densities (expressed in pA/pF) were calculated as peak K<sup>+</sup> currents at 0mV divided by cell capacitance. To generate conductance–voltage curves, the cells were held at –80mV, then depolarized for 1.5 seconds from –120 to +20mV in 10mV increments, followed by an isopotential pulse at 0mV of 300-millisecond duration. The current values recorded at the beginning of the 0mV pulse were measured, normalized, and expressed as a function of the preceding voltages. The data were then fit to a Boltzmann distribution of the following form:  $y = \max/[1 + \exp((V_{1/2} - V)/k)]$ , where  $V$  is the test potential,  $V_{1/2}$  the half-activation potential, and  $k$  the slope factor.

### **Multistate Protein Modeling**

Three-dimensional models of KCNQ2 and KCNQ3 channels were generated using as templates the coordinates of 6 different states of Kv1.2/2.1 paddle chimera (PDB accession number 2R9R) by SWISS-MODEL (University of Basel, Basel, Switzerland). The models were optimized through all-atom energy minimization by the GROMOS96 implementation of Swiss-PDBViewer and analyzed using both the DeepView module of Swiss-PDBViewer (v4.0.1; <http://spdbv.vital-it.ch/>) and PyMOL (<http://www.pymol.org/>), as described.<sup>4,12</sup> Sequence alignment was performed using Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo/>).

### **Statistics**

The probability that a sequencing result reflected postzygotic mosaicism was assessed by the binomial exact test, based on the expectation that heterozygous germline variants will be represented in approximately 50% of read observations. Electrophysiological data are expressed as mean  $\pm$  standard error of the mean. Statistically significant differences were evaluated with the Student  $t$  test or with analysis of variance followed by the Student–Newman–Keuls test, with the threshold set at  $p < 0.05$ .

## **Results**

### **KCNQ3 DNVs Are Associated with a Novel Phenotype Consisting of Neurodevelopmental Delay, Autistic Features, and Sleep-Activated Near-Continuous Multifocal Spikes**

**Index Case (Patient 1).** A 30-month-old boy with global developmental delay and ASD presented with episodes of head nodding and stumbling that raised concern for seizures. His development had been normal through the first year, but he did not walk until 18 months and he had no expressive language. He had poor eye contact, impaired joint attention, and did not respond to his name, and his behaviors were notable for stereotypies and echolalia. One week prior to presentation, his mother became concerned by worsening balance with increased falls and more impulsive and aggressive behavior. He was admitted for evaluation with a differential diagnosis that included seizures as a cause of his exacerbated motor impairment. The events of concern were captured on long-term video-EEG monitoring and did not show an EEG correlate. His EEG background, however, was diffusely slow with frequent multifocal spike-and-wave discharges, most prominent in the posterior leads. These discharges increased in amplitude (to >300 $\mu$ V) and in abundance during sleep, becoming present for >80% of the sleep record. Given these findings in the clinical context of worsened behaviors and motor performance, the treating physicians were concerned for an epileptic encephalopathy. Treatment with high-dose oral diazepam (1mg/kg) led to rapid resolution of the epileptiform abnormalities, and improvements were subsequently noted across multiple developmental domains by his parents and therapists. Trio exome sequencing revealed a heterozygous *KCNQ3* de novo variant predicted to result in the missense change R230H.

### **Cohort Genotypes and Phenotypes**

We identified 10 other patients with NDD and variants in *KCNQ3* predicted to change R230 and R227 (Tables 1 and 2). These included 2 additional patients with R230H, 5 patients with R230C, 1 patient with R230S, and 2 patients with R227Q. Next generation sequencing revealed mosaicism

**TABLE 1. Clinical Features of KCNQ3 Gain-of-Function Variants**

Case	Variant	Age, yr/Sex	Neurodevelopment	Other Features	Brain MRI
1	c.689G>A, p.R230H	4/M	Walked at 18 mo, ataxic gait; few words; ASD diagnosis at 21 mo, ID, echolalia; impulsive, aggressive behavior; stereotypies	Hypotonia, esotropia	Normal at 37 mo
2	c.688C>A, p.R230S	23/M	Walked at 23 mo; ataxic gait; nonverbal, autistic features	Hypotonia	Mild hypoplasia of corpus callosum, mild cerebellar atrophy at 19 mo
3	c.689G>A, p.R230H <sup>a</sup>	5/M	Head lag at 6 mo; sat at 13 mo; walked at 25 mo; ataxic gait; nonverbal (few words, then regressed); impulsive, repetitive behaviors, poor eye contact	Hypotonia, exotropia	Mild T2 hyperintensities in the bilateral peritrial white matter at 15 mo and 3.5 yr
4	c.688C>T, p.R230C	20/F	Sat at 12 mo; walked at 24 mo; 4–5 words; moderate ID; stereotypies; aggressive behavior	Exotropia, possible CVI	Normal at 4 yr, 6 yr, and 15 yr
5	c.688C>T, p.R230C	4/F	Sat at 13 mo; walked with assistance at 34 mo; 2 words at 34 mo; poor eye contact	Birth at 34 wk, hypotonia, strabismus	Diminished white matter, right > left, and abnormal frontal sulcation at 13 mo and 32 mo
6	c.688C>T, p.R230C	11/M	Walked at 23 mo; ASD diagnosis at 3 yr; nonverbal (few words then regressed); impulsive; self-injurious behavior	Strabismus	Normal at 10 mo
7	c.689G>A, p.R230H, 18% mosaic	5/M	Walked at 14 mo, ataxic gait; fine motor impairment; words by 2 yr; sentences by 3 yr; ASD diagnosis at 3 yr	Hypotonia, strabismus	Normal at 4 yr
8	c.688C>T, p.R230C	21/M	Walked by 18 mo; nonverbal; ASD; severe ID	Left esotropia	Normal at 3 yr
9	c.688C>T, p.R230C	8/M	Sat at 12 mo; walked at 26 mo; nonverbal; anxiety, aggressive behavior; autistic features (stereotypies, poor eye contact)	Hypotonia	Nonspecific white matter lesions at 18 mo
10	c.680G>A, p.R227Q	9/F	Walked at 22 mo; speaks in 2–3-word sentences; ASD diagnosis at 2 yr; stereotypies, echolalia	Hypotonia	Normal at 9 yr and 12 yr
11	c.680G>A, p.R227Q	18/F	Walked at 12 mo; words at 3 yr, sentences by 6 yr; echolalia, stereotypies, sensory issues; dysarthria; FSIQ 42; assistance to brush teeth, comb hair		Normal at 6 yr

<sup>a</sup>Unaffected mother with low-level mosaicism (5%–6%).

ASD = autism spectrum disorder; CVI = cortical visual impairment; F = female; FSIQ = full-scale intelligence quotient; ID = intellectual disability; M = male; MRI = magnetic resonance imaging.

**TABLE 2. Electroclinical Features of Patients with KCNQ3 Gain-of-Function Variants**

Patient/Variant	EEG	Seizures	AEDs
1/R230H	Diffusely slow with posterior spikes in wakefulness; MSES in sleep (posterior predominant EDs) at 30 mo	No (staring and jerks recorded at 30 mo)	For MSES at 30 mo: DZP (++), CLB (++)
2/R230S	Spikes (L) at 12 mo; MSES at 18 mo and 4 yr (R>L); spikes (R>L) at 8 yr; no spikes (awake) at 12 yr and 19 yr	Staring spells at 3 yr	VPA
3/R230H	Diffusely slow with posterior spikes in wakefulness; MSES at 3.5 yr and 4.5 yr (posterior predominant EDs)	No (staring spells recorded at 3 yr)	LEV at 3.5 yr; DZP (++) for MSES at 4.5 yr
4/R230C	Normal at 4.5 yr; diffusely slow electrical activity at 16 yr	GTC from 13 yr; atonic seizures at 15 yr	VPA, CLB, LCM (all for seizures)
5/R230C	Frequent sleep-activated L posterior > R central EDs at 3 yr	No	None
6/R230C	MSES at 6 yr (L>R central and temporal EDs)	GTC from 10 mo; atonic seizures; absence seizures	VPA, LEV, OXC, RUF, KD (all for seizures)
7/R230H mosaic	Normal at 4.5 yr	No	None
8/R230C	Diffusely slow with posterior spikes in wakefulness; MSES at 30 mo, 3.5 yr, 4 yr, 4.5 yr, and 5 yr (posterior predominant EDs)	Staring spells reported at 2 yr	VPA for staring spells; for MSES: LTG, CS (+), CLB
9/R230C	Diffusely slow in wakefulness; MSES at 3.5 yr, 4 yr, 4.5 yr, 5.5 yr, 6.5 yr	No	For MSES: CS (+), ETX, CLB
10/R227Q	Frequent sleep-activated L frontotemporal EDs at 9 yr	No	None
11/R227Q	Normal at 2.5 yr (awake only); normal at 18 yr (awake only)	Staring spells reported at 2.5 yr	None

+ = partial response; ++ = response; AEDs = antiepileptic drugs; CLB = clobazam; CS = corticosteroids; DZP = diazepam; EDs = epileptiform discharges; EEG = electroencephalogram; ETX = ethosuximide; GTC = generalized tonic-clonic seizure; KD = ketogenic diet; L = left; LCM = lacosamide; LEV = levetiracetam; LTG = lamotrigine; MSES = multifocal status epilepticus during sleep; OXC = oxcarbazepine; R = right; RUF = rufinamide; VPA = valproic acid.

in 1 parent and 1 proband. The asymptomatic mosaic mother of Patient 3 carried the variant in 3 of 50 reads (6%,  $p < 10^{-8}$ , binomial exact test). Aside from Patient 3, all variants were confirmed to be absent in parental samples. The DNA sequencing of Patient 7 showed R230H in 22 of 121 reads (18%,  $p < 10^{-8}$ ). R227Q, R230C, and R230S were absent from the population database gnomAD.<sup>18</sup> Interestingly, 1 of 122,950 individuals in the gnomAD dataset showed mosaic presence of R230H (45/145 reads, 31%,  $p = 2.9 \times 10^{-6}$ ),<sup>18,19</sup>

similar to Patient 7. Clinical information was not available regarding the gnomAD mosaic individual. In silico analysis predicted each of these variants to be deleterious with high probability (PolyPhen-2 > 0.999, SIFT = 0, CADD score > 30).<sup>20–22</sup>

For genome-wide significance as an NDD gene, our 11 patients would need to have been observed from a cohort no larger than 47,000 individuals ( $p = 2.40e-06$ , CCDS22).<sup>23</sup> Patient 6 was identified in an Epi4K cohort of 264

individuals,<sup>16</sup> but the method of ascertainment of most our other patients made precise determination of the denominator impossible, precluding formal calculation.

All 11 patients had some degree of ID and delays across multiple developmental domains, coming to clinical attention between the ages of 4 and 18 months. Delayed language was universal, but patients often presented with concurrent or preceding gross motor delays. Patient 3 did not develop head control until after 6 months. Four patients were late to sit, and all but 2 individuals (Patients 7 and 11) were delayed in walking. Although all patients ultimately walked, walking was often characterized as broad-based and unsteady with poor balance, variably reported as ataxic.

Language development was abnormal in all cases. Three patients were nonverbal. Five developed single words, but 2 of these subsequently regressed to become nonverbal. Patient 7, mosaic for R230H, and the 2 patients (10 and 11) who carried the R227Q variant had language delay with first words at 2 or 3 years, but were ultimately able to speak in sentences.

ASD was diagnosed in 5 of 11 (45%) patients, and autistic features were reported in the remaining 6. Stereotypies, mouthing nonfood objects, and aggressive, impulsive, and self-injurious behaviors were common features. Hypotonia and strabismus were each reported in 7 of 11 (64%) individuals. Brain magnetic resonance imaging (MRI) studies were normal or showed nonspecific abnormalities. The MRI of Patient 5 showed diminished white matter and abnormal frontal sulcation not consistent with acquired injury, although he had a history of preterm delivery at 34 weeks of gestation.

Two patients (4 and 6) were diagnosed with generalized tonic-clonic seizures from 13 years and from 10 months of age, respectively. Atonic seizures were also reported for these patients, as well as absence seizures for Patient 6. The remaining patients were not diagnosed with seizures (9/11, 82%). No patients had seizures in the neonatal period.

All 11 patients had EEGs recorded at some point between 1 and 10 years of age, and 8 of them (73%) had focal or multifocal spikes that were markedly activated by sleep. In 6 of 9 patients (67%) with sleep EEGs between 18 months and 6 years of age, epileptiform discharges became near-continuous during sleep. For 4 of these children (Patients 1, 2, 3, and 8), parents noticed recurrent episodes of unresponsive staring or deteriorating motor function with subtle jerks or loss of tone that led to assessment with prolonged video-EEG recording. Although the events of concern could not always be captured, the spikes observed were not time-locked with jerks, loss of tone, or unresponsive staring. In 5 cases (Patients 1, 2, 3, 8, and 9), the discovery of the markedly abnormal sleep EEG in


this clinical context raised concern for epileptic encephalopathy, leading physicians to treat with antiseizure medications including high-dose diazepam with the goal of reducing or eliminating the epileptiform abnormalities. The clinical response to treatments varied; some benefits were reported, although no worsening was seen when the antiseizure medications were discontinued. Treatment with high-dose oral diazepam (Patients 1 and 3) or corticosteroids (Patients 8 and 9) was followed by reduction of the sleep-activated spikes on EEG, but with inconsistent effects on behavior.

### **KCNQ3 R227 and R230 Variants Exhibit GoF with Increased Current Density and Hyperpolarized Activation Voltage Dependence**

KCNQ3 R227 (R1) and R230 (R2) are the outermost of the positively charged residues of the S<sub>4</sub> voltage sensor (Fig 1A); in KCNQ2, R1 and R2 correspond to R198 and R201, respectively (see Fig 1B). The functional properties of channels formed by KCNQ3 R227Q or R230C/H/S variants were characterized as homomers and as heteromers with KCNQ2 subunits.

Wild-type homomeric KCNQ3 channels generated small K<sup>+</sup>-selective and voltage-dependent currents that activated around -60mV and displayed a V<sub>1/2</sub> of -38mV (see Fig 1C, D; Table 3). At a holding voltage of -80mV, the vast majority of KCNQ3 channels were closed; therefore, the ratio between the currents measured at the beginning of the depolarization step (I<sub>Inst</sub>) and those at the end of the 0mV depolarization (I<sub>steady-state</sub>) was close to zero (see Table 3). By contrast, homomeric KCNQ3 channels in which the charged side chain at R230 was substituted by cysteine, serine, or histidine residues (R2C, R2S, and R2H, respectively) showed an almost complete loss of time-dependent current activation kinetics; as a result, the I<sub>Inst</sub>/I<sub>steady-state</sub> ratio was close to unity. Similar, although quantitatively smaller, effects were observed upon neutralization of the R227 residue with glutamine (R1Q); KCNQ3 R227Q channels retained voltage-dependent gating, although with a drastic (>70mV) hyperpolarization of the voltage requirement for activation. Notably, this functional change is qualitatively similar but quantitatively larger than that produced by the corresponding substitution (R198Q) in KCNQ2 (-30mV).<sup>24</sup>

In addition, the amplitude of K<sup>+</sup> current carried by each of the 4 mutant channels at depolarized membrane potentials was increased approximately 10-fold, compared to wild-type KCNQ3 channels (see Table 3). In contrast to the dramatic changes in voltage-sensitivity and current size described in all 4 mutant channels, other important properties, such as the sensitivity to blockade by tetraethylammonium (TEA), a pharmacological feature discriminating between KCNQ3 and KCNQ2 channels, and the K<sup>+</sup> reversal potential,



**FIGURE 1:** Functional consequences of the R227Q and R230C/S/H variants in KCNQ3. (A) Topological representation of a single KCNQ3 subunit. The red arrows highlight the position of the first 2 arginines (R1 and R2) along the S<sub>4</sub> primary sequence, where variants of interest in the present study are located. (B) Sequence alignment of the 4 transmembrane regions (S<sub>1</sub>, S<sub>2</sub>, S<sub>3</sub>, and S<sub>4</sub>) of the voltage-sensing domain of KCNQ3 and KCNQ2 subunits. Residues relevant to the present study are colored as follows: green for positively charged, pink for negatively charged, and orange for nonpolar. Among polar amino acids, C is in light blue, whereas S is in violet. R1, R2, R4, R5, and R6 refer to the positively charged arginines numbered according to their position along the S<sub>4</sub> primary sequence. (C) Macroscopic currents from the KCNQ3 (WT), KCNQ3 R227Q (R1Q), KCNQ3 R230C (R2C), KCNQ3 R230S (R2S), or KCNQ3 R230H (R2H) homomeric channels in response to the indicated voltage protocol. Inset shows an enlarged view of KCNQ3 traces. The arrows on the voltage protocol indicate the time chosen for current analysis, as explained in the text. Current scale, 100pA; time scale, 0.2 seconds. (D) Conductance/voltage curves for KCNQ3 (WT, filled circles), KCNQ3 R227Q (R1Q, empty circles), KCNQ3 R230C (R2C, inverted triangles), KCNQ3 R230S (R2S, triangles), or KCNQ3 R230H (R2H, squares) homomeric channels, as indicated. Continuous lines are Boltzmann fits to the experimental data. Each data point is the mean standard error of 9-21 cells recorded in at least 3 separate experimental sessions.

indicative of channel selectivity for K<sup>+</sup> ions, were unchanged from the wild type (see Table 3).

To mimic the genetic condition of patients, who carry a single mutant allele, and considering that I<sub>KM</sub> in adult neurons is mainly formed by tetrameric coassembly of KCNQ2 and KCNQ3 subunits, we transfected CHO cells with *KCNQ2* and *KCNQ3* cDNAs at a 1:1 ratio (to mimic the genetic balance of normal individuals), and *KCNQ2* + *KCNQ3* + mutant *KCNQ3* at a 1:0.5:0.5 ratio (to mimic the genetic balance of affected individuals). Coexpression of KCNQ3 R227Q, R230C, R230H, or R230S subunits with KCNQ2 and KCNQ3 subunits caused a statistically significant hyperpolarization in activation voltage-dependence of about 6mV, without affecting current density or TEA sensitivity when compared to KCNQ2 + KCNQ3 channel controls (see Table 3).

### Mechanistic Basis for the GoF by KCNQ3 R227 and R230 Variants

We used a model based on the atomic structure of Kv1.2/2.1 channels to analyze the mechanistic basis for the functional effects observed. In the resting state, the positively charged side chains of R227 (R1) and R230 (R2) in the KCNQ3 VSD establish ionized hydrogen bonds with nearby polar or charged residues: R227 with C136 in S<sub>1</sub>, and R230 with E170 and D202 in S<sub>2</sub> and S<sub>3</sub>, respectively (Fig 2). These interactions are all lost when the S<sub>4</sub> moves toward the extracellular space during activation<sup>24</sup>; therefore, the R227Q or the R230C/S/H substitutions are predicted to selectively destabilize the resting (closed) conformation of the VSD, possibly explaining the observed GoF effects. It is noteworthy that R198 in KCNQ2 (R1, corresponding to KCNQ3 R227), in addition to C106 (corresponding to KCNQ3 C136), also establishes a strong hydrogen bond with S110; in KCNQ3, this position is occupied by a nonpolar residue (A140) that is unable to interact with R227 (R1). That the R227 residue in KCNQ3 only establishes a weak hydrogen bond with the nearby C residue, whereas the corresponding R198 residue in KCNQ2 is also engaged in a stronger hydrogen bond with S110 renders the VSD resting state less stable in KCNQ3 when compared to KCNQ2, likely contributing to the lower activation midpoint of the former,<sup>12</sup> and possibly to the more dramatic V<sub>1/2</sub> hyperpolarizing effect of the KCNQ3 R227Q substitution (Q1) when compared to the R198Q substitution in KCNQ2 (Q1).<sup>24</sup>

### Discussion

Inherited variants in *KCNQ3* are known to be associated with BFNE. Our series describes the novel phenotype in patients with de novo *KCNQ3* missense variants at R227 and R230, characterized by NDD, ASD, and sleep-activated near-continuous multifocal spikes, and increases



**TABLE 3. Biophysical and Pharmacological Properties of Channels Carrying *KCNQ3* Variants**

	No.	$V_{1/2}$ , mV	k, mV/efold	$I_{Inst}/I_{steady-state}$	Current Density, pA/pF	$E_{K}$ , mV	Blockade by TEA, %		
							0.3mM	3mM	30mM
KCNQ3	21	$-38.4 \pm 1.0$	$7.1 \pm 0.4$	$0.04 \pm 0.02$	$10.6 \pm 1.3$	$-79.0 \pm 0.1$	$6.4 \pm 1.8$	$13.0 \pm 3.4$	$61.7 \pm 5.7$
KCNQ3 R1Q	9	$-112.0 \pm 2.4^a$	$10.8 \pm 0.9^a$	$0.91 \pm 0.02^a$	$89.6 \pm 17.5^a$	$-79.9 \pm 0.3$	–	–	$61.1 \pm 6.8$
KCNQ3 R2C	12	–	–	$1.00 \pm 0.01^a$	$121.0 \pm 21.0^a$	$-79.9 \pm 0.3$	–	–	$58.6 \pm 13$
KCNQ3 R2S	16	–	–	$0.98 \pm 0.03^a$	$89.7 \pm 12.2^a$	$-80.1 \pm 0.1$	–	–	$66.1 \pm 6.1$
KCNQ3 R2H	12	–	–	$0.98 \pm 0.02^a$	$132.2 \pm 20.0^a$	$-79.3 \pm 0.4$	–	–	$70.9 \pm 7.3$
KCNQ2 + KCNQ3	16	$-33.6 \pm 1.2$	$13.6 \pm 0.4$	$0.04 \pm 0.02$	$133.5 \pm 19.0$	–	$15.6 \pm 3.1$	$50.5 \pm 3.1$	$78.8 \pm 5.6$
KCNQ2 + KCNQ3 + KCNQ3 R1Q	9	$-39.5 \pm 3.0^b$	$14.7 \pm 0.8$	$0.04 \pm 0.01$	$101.3 \pm 20.2$	–	$19.3 \pm 2.0$	$44.1 \pm 4.3$	$85.3 \pm 2.1$
KCNQ2 + KCNQ3 + KCNQ3 R2C	9	$-39.9 \pm 3.7^b$	$15.3 \pm 0.7$	$0.10 \pm 0.03^b$	$108.8 \pm 16.9$	–	$14.0 \pm 6.2$	$47.1 \pm 9.9$	$77.0 \pm 7.3$
KCNQ2 + KCNQ3 + KCNQ3 R2S	14	$-39.0 \pm 1.5^b$	$15.0 \pm 0.6$	$0.07 \pm 0.02^b$	$116.7 \pm 12.0$	–	$12.9 \pm 2.3$	$43.6 \pm 8.2$	$80.1 \pm 6.5$
KCNQ2 + KCNQ3 + KCNQ3 R2H	14	$-39.5 \pm 1.5^b$	$14.2 \pm 0.4$	$0.08 \pm 0.02^b$	$123.0 \pm 15.5$	–	$20.8 \pm 3.1$	$47.4 \pm 2.5$	$78.8 \pm 3.2$

<sup>a</sup> $p < 0.05$  versus KCNQ3.  
<sup>b</sup> $p < 0.05$  versus KCNQ2 + KCNQ3.  
TEA = tetraethylammonium.

the number of reported patients with this mutational hotspot to 16. The R230C, R230H, and R230S variants all resulted in strong GoF effects, whereas similar but smaller effects were exhibited by R227Q.

Although formal calculation of genome-wide significance was not possible, given our inability to know the total number of individuals sequenced for NDD, we calculated an upper limit of 47,000. Our collaborative study is highly unlikely to have drawn from such a large population. Supporting this, the largest NDD cohort from which cases have been identified to date, the Deciphering Developmental Disorders Study, was smaller than this limit by an order of magnitude and identified 2 such patients.<sup>10</sup> The similarity of clinical presentation and the complementary functional work we present provide additional support for *KCNQ3* as an NDD gene.


Patients with *KCNQ3* GoF variants at R227 and R230 presented with developmental delay within the first 2 years of life, with more than one-third of the cohort presenting before 12 months. Patients with R230C/H/S variants were usually ambulatory by 2 years of age, but were either nonverbal or had single words only and were cognitively impaired with ASD or autistic features. Patient 7, whose testing revealed mosaicism for R230H, had a relatively milder phenotype, and the mother of Patient 3, with low-level mosaicism for R230H, was unaffected. The NDD of the 2 patients with R227Q was also less severe, consistent with our findings of milder alteration of in vitro functional properties of channels carrying this variant compared to

those carrying R230C/H/S variants. Although these findings are suggestive of a positive correlation between the extent of GoF and severity, current data are insufficient for proper statistical assessment, which will have to wait for larger numbers of patients.

Previous studies sequencing cohorts of patients with DEE, NDD, ID, and cortical visual impairment have identified 1 patient with R227Q, 3 with R230C, and 2 with R230S DNVs in *KCNQ3*.<sup>8–11,16</sup> Although limited, the clinical features reported in those five patients (Table 4) seem consistent with the ones in our cohort.

### **Multifocal Status Epilepticus during Sleep**

EEG recordings showed sleep-activated spikes in all but 2 patients monitored during sleep. In 6 patients who had EEGs performed between 1.5 and 6.5 years of age, spikes became near-continuous during sleep, raising concerns for epileptic encephalopathy in the clinical setting. Continuous spike and wave during slow wave sleep is an epilepsy syndrome characterized by neurocognitive regression or stagnation associated with near-continuous diffuse spike-waves occurring during sleep, an electrographic pattern referred to as electrical status epilepticus during slow sleep. When we analyzed the EEGs, we found that the spikes were multifocal with a posterior predominance, which suggested the term “multifocal status epilepticus during sleep” (MSES). Some of our patients had language regression, but we do not have longitudinal testing to determine the timing and extent of regression or developmental plateauing or correlate it with the appearance of



**FIGURE 2: Structural modeling of KCNQ3 voltage-sensing domain (VSD) in resting and activated states, and comparison with KCNQ2. (A)** Structural model of the resting (left panel) and activated (right panel) gating states of the VSD from a single KCNQ3 subunit, as indicated. Residues relevant to the present study are colored as follows: green for positively charged, pink for negatively charged, orange for nonpolar, and blue and purple for polar (C is in light blue, S is in violet). R1, R2, R4, R5, and R6 refer to the positively charged arginines numbered according to their position along the  $S_4$  primary sequence. **(B)** An enlarged view of the resting state of the VSD of KCNQ3 (top left panel) and KCNQ2 (top right panel). Lower panels highlight the ionic interactions established when the R1 residues are substituted with Q (Q1) in KCNQ3 (left) or KCNQ2 (right) subunits. In all panels, the dashed red lines indicate ionic interactions among residues.

MSES. In most patients in whom MSES was detected, EEG monitoring was prompted by concern for seizures. Although these patients were not diagnosed with seizures, the presence of near-continuous spikes during sleep led to treatment based on the concept that reducing the abundance of epileptiform abnormalities may prevent or reverse developmental stagnation or regression.<sup>25,26</sup> Our numbers are too small to draw conclusions about electrographic responses to standard therapies, such as diazepam,<sup>27</sup> and more recently described treatments, such as amantadine, were not used.<sup>28</sup>

Two patients in our cohort were diagnosed with generalized tonic-clonic seizures, atonic seizures, and absence seizures, although their events were never captured on EEG. Absence epilepsy/seizures were intriguingly also noted in the limited clinical details for 2 patients with *KCNQ3* variants in previously reported cohorts (see Table 4).<sup>10,11</sup> However, the full spectrum of epileptic disorders in patients with *KCNQ3* GoF variants awaits further characterization with ictal video-EEG recordings and classification of the events. Our study has the limitations of being retrospective; evaluation (eg, cognitive/behavioral testing, timing, and length of EEG recordings) and treatment (including medication selection and duration of treatment) were determined at the discretion of the treating physicians and did not follow a research protocol.

### ***KCNQ3* and *KCNQ2* Genotypes and Phenotypes**

Brain *KCNQ2* and *KCNQ3* subunits coassemble as heteromeric channels,<sup>29</sup> and inherited LoF missense variants in these genes cause an autosomal dominant phenotype, BFNE.<sup>30–32</sup> Most de novo *KCNQ2* LoF variants result in a severe DEE with seizure onset in the neonatal period.<sup>6,15,17,33</sup> However, de novo *KCNQ2* GoF variants R201C and R201H are associated with a distinct neonatal syndrome characterized by nonepileptic myoclonus, pathological breathing, and a suppression-burst EEG pattern in the absence of seizures.<sup>14</sup> We now report that de novo GoF variants at the *KCNQ3* R230 position, homologous to *KCNQ2* R201, cause NDD associated with ASD/autistic features and MSES without neonatal seizures. Whereas the *KCNQ2* R198Q variant has been found recurrently in patients with West syndrome without prior neonatal seizures,<sup>24</sup> we found the homologous *KCNQ3* variant, R227Q, in 2 patients with less severe NDD without any history of seizures. These findings further extend the phenotypes associated with *KCNQ2* and *KCNQ3* GoF variants, which have in common the absence of neonatal seizures, the main characteristic of LoF variants (Table 5).

Our understanding of the mechanism by which GoF changes in *KCNQ3* subunits result in the described clinical phenotype with NDD and without neonatal seizures is limited by the lack of in vivo studies. In particular, it is unclear why the LoF condition presents in the neonatal period, whereas the GoF condition results in cognitive and behavioral disturbances that only become apparent later. Interestingly, a parallel but reverse genotype–phenotype correlation has been reported for *SCN2A*-related disorders, where GoF results in early epilepsy and LoF imparts neurodevelopmental disability with autistic features and more variable epilepsy phenotypes with later onset.<sup>34</sup> This similarity may not be coincidental, as both channels are localized at the axon initial segment and seizures in early epilepsy caused by *KCNQ3* LoF variants, like

**TABLE 4. Previously Published Patients with *KCNQ3* R227 and R230 Variants**

Publication /Case ID	Variant	Sex	Neurodevelopment	Other Features	EEG	Seizures	Brain MRI
Rauch et al 2012/TUTLN	c.688C>T, p.R230C	F	Sat at 12 mo, walked at 24 mo; nonverbal at 42 mo; moderate ID; autistic, aggressive, anxious	Strabismus	Multifocal sharp waves, sharp slow waves	No	6-mo MRI: "hypointensity in left ventricle"
Grozeva et al 2015/5410783	c.688C>A, p.R230S <sup>a</sup>	F	Nonsyndromic ID				
Bosch et al 2016/24	c.688C>T, p.R230C	F	ID at 4 yr	Cortical visual impairment		Absence of epilepsy	
DDD 2017/261649	c.688C>A, p.R230S	F	Broad-based gait; delayed speech and language; severe ID; recurrent hand flapping	Strabismus, microcephaly		Absence of seizures	
DDD 2017/272471	c.680G>A, p.R227Q	M	Global developmental delay				

<sup>a</sup>Inheritance unknown.

DDD = Deciphering Developmental Disorders Study; EEG = electroencephalogram; F = female; ID = intellectual disability; M = male; MRI = magnetic resonance imaging.

those caused by *SCN2A* GoF variants, are responsive to sodium channel blockers, such as carbamazepine.<sup>35,36</sup>

The reason for the differences in phenotypes between *KCNQ2* and *KCNQ3* variants at homologous positions is unknown, and fuller investigation of this will likely require in vivo developmental studies. In rodents, the ratio of *KCNQ3* to *KCNQ2* expression is low at birth and increases during postnatal development.<sup>37</sup> Similar findings have been shown in the human brain,<sup>38</sup> and may explain the earlier

onset and more severe disability of *KCNQ2* GoF pathogenic variants compared to *KCNQ3*.

Whereas the features of neonatal onset *KCNQ2*- and *KCNQ3*-related epilepsy are distinctive,<sup>35,39</sup> enabling early recognition of the phenotype and genetic testing, global NDD is clinically and genetically heterogeneous. The prevalence of *KCNQ3* R227 and R230 variants in the general population of children with NDDs is unknown, but is likely under-recognized, as neither exome sequencing nor sleep

**TABLE 5. Gain-of-Function Variants in the Voltage Sensor Domain S4 Segments of *KCNQ2* and *KCNQ3* Have Diverse Electroclinical Phenotypes**

S4 Arginine	<i>KCNQ2</i>		<i>KCNQ3</i>	
	Known Variants	Phenotypes	Known Variants	Phenotypes
R1	R198Q	West syndrome (hypsarhythmia, infantile spasms, emergence of developmental delay) without preceding neonatal seizures or encephalopathy	R227Q	Neurodevelopmental disability: verbal, with autism spectrum disorder or autistic features and sleep-activated spikes
R2	R201C, R201H	Profound neonatal onset encephalopathy with nonepileptic myoclonus, burst-suppression EEG and apnea, with West syndrome later in infancy	R230C, R230H, R230S	Neurodevelopmental disability: nonverbal, with autism spectrum disorder or autistic features and multifocal status epilepticus during sleep

EEG = electroencephalogram.

EEG is currently routinely included in the evaluation of children with NDD and autism.

### **A Monogenic Cause of NDD and Autism**

Monogenic subtypes of autism are increasingly being identified, particularly when comorbid with ID.<sup>40,41</sup> Epilepsy, ID, and autism often co-occur and share genetic causes and perhaps underlying mechanisms.<sup>42</sup> As near-continuous epileptiform activity during sleep may interfere with development, and treatment with benzodiazepines may be successful at abolishing the electrographic pattern, sleep EEG recording for patients with NDD/ID with autism may have clinical utility.

Limitations of this study arise from the rarity of the disorder, and include differences in patient evaluation between sites, and the potential for ascertainment bias, as parents of severely affected children may be more likely to seek clinical genetic evaluation and participate in research. Additional work, including standardized assessment of a larger patient group, will enable further characterization of *KCNQ3* GoF pathogenic variants.

### **Conclusion**

Our findings show that GoF missense variants at R230 and R227 in *KCNQ3* do not cause neonatal epilepsy, and instead result in a novel phenotype characterized by NDD with ASD and MSES. Our work provides another example of the delineation of distinct phenotypes associated with different classes of variants in ion channel genes, expands the phenotypic spectrum associated with pathogenic variants in *KCNQ3*, complements the GoF phenotypes reported for *KCNQ2*, and adds *KCNQ3* to genetic causes of autism.

### **Acknowledgment**

The present work was supported by the Telethon Foundation (GGP15113) and by the Italian Ministry for University and Research (PRIN 2017ALCR7C) to M.T.; the Italian Ministry for University and Research (Project Scientific Independence of Researchers 2014 RBSI1444EM and PRIN 2017YH3SXX) and the University of Naples “Federico II” and Compagnia di San Paolo within the STAR Program “Sostegno Territoriale alle Attività di Ricerca” (project number 6-CSP-UNINA-120) to F.M.; the Italian Ministry of Health Ricerca Finalizzata Giovani Ricercatori 2016 (project GR-2016-02363337) and the Italian Ministry for University and Research (PRIN 2017ALCR7C) to M.V.S.; National Institute of Neurological Disorders and Stroke (R01 NS49119 and U54 NS108874) to E.C.C.; the Jack Pribaz Foundation (E.C.C. and S.W.), the *KCNQ2* Cure Alliance (E.C.C.

and S.W.), and the Miles Family Fund (E.C.C.). The present work was also supported by the University Research Fund—University of Antwerp (FFB180053) and Scientific Research Flanders (1861419N) to S.W. and by the NIH National Institute of Neurological Disorders and Stroke (R01 NS069605) to H.C.M. Genome sequencing for Patient 11 was performed by the SNP&SEQ Technology Platform in Uppsala, Sweden, in collaboration with Lars Feuk. This facility is part of the National Genomics Infrastructure Sweden and Science for Life Technologies. The platform is supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. Exome sequencing for Patient 4 was ascertained in the Duke Genome Sequencing Clinic, supported by the Duke University Health System, Durham, NC.

We thank the patients and their families for participation in this research, and the *KCNQ2* Cure Alliance and Jack Pribaz Foundation for collaboration and parent referrals.

### **Author Contributions**

Acquisition and analysis of data: all authors. Study concept and design: T.T.S., E.C.C., M.T., and M.R.C. Drafting the text and preparing the figures: T.T.S., F.M., E.C.C., M.T., and M.R.C.

### **Potential Conflicts of Interest**

Nothing to report.

---

### **References**

1. Wang HS, Pan Z, Shi W, et al. *KCNQ2* and *KCNQ3* potassium channel subunits: molecular correlates of the M-channel. *Science* 1998; 282:1890–1893.
2. Grinton BE, Heron SE, Pelekanos JT, et al. Familial neonatal seizures in 36 families: clinical and genetic features correlate with outcome. *Epilepsia* 2015;56:1071–1080.
3. Miceli F, Striano P, Soldovieri MV, et al. A novel *KCNQ3* mutation in familial epilepsy with focal seizures and intellectual disability. *Epilepsia* 2015;56:e15–e20.
4. Ambrosino P, Freri E, Castellotti B, et al. Kv7.3 compound heterozygous variants in early onset encephalopathy reveal additive contribution of C-terminal residues to PIP2-dependent K(+) channel gating. *Mol Neurobiol* 2018;55:7009–7024.
5. Orhan G, Bock M, Schepers D, et al. Dominant-negative effects of *KCNQ2* mutations are associated with epileptic encephalopathy. *Ann Neurol* 2014;75:382–394.
6. Weckhuysen S, Mandelstam S, Suls A, et al. *KCNQ2* encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. *Ann Neurol* 2012;71:15–25.
7. Long SB, Campbell EB, Mackinnon R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. *Science* 2005;309: 903–908.
8. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet* 2012;380:1674–1682.

9. Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted next-generation sequencing analysis of 1,000 individuals with intellectual disability. *Hum Mutat* 2015;36:1197–1204.
10. Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 2017;542:433–438.
11. Bosch DG, Boonstra FN, de Leeuw N, et al. Novel genetic causes for cerebral visual impairment. *Eur J Hum Genet* 2016;24:660–665.
12. Miceli F, Soldovieri MV, Ambrosino P, et al. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. *J Neurosci* 2015;35:3782–3793.
13. Millichap JJ, Miceli F, De Maria M, et al. Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant. *Epilepsia* 2017;58:e10–e15.
14. Mulkey SB, Ben-Zeev B, Nicolai J, et al. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. *Epilepsia* 2017;58:436–445.
15. Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. *Neurol Genet* 2016;2:e96.
16. Consortium EK, Project EPG, Allen AS, et al. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217–221.
17. Miceli F, Soldovieri MV, Ambrosino P, et al. Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K(v)7.2 potassium channel subunits. *Proc Natl Acad Sci U S A* 2013;110:4386–4391.
18. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–291.
19. Genome Aggregation Database. Available at: <http://gnomad.broadinstitute.org/variant/8-133192492-C-T>. Accessed August 1, 2018.
20. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003;31:3812–3814.
21. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods* 2010;7:248–249.
22. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310–315.
23. Jiang Y, Han Y, Petrovski S, et al. Incorporating functional information in tests of excess de novo mutational load. *Am J Hum Genet* 2015;97:272–283.
24. Gourgy-Hacohen O, Kornilov P, Pittel I, et al. Capturing distinct KCNQ2 channel resting states by metal ion bridges in the voltage-sensor domain. *J Gen Physiol* 2014;144:513–527.
25. Robinson RO, Baird G, Robinson G, et al. Landau-Kleffner syndrome: course and correlates with outcome. *Dev Med Child Neurol* 2001;43:243–247.
26. Scholtes FB, Hendriks MP, Renier WO. Cognitive deterioration and electrical status epilepticus during slow sleep. *Epilepsy Behav* 2005;6:167–173.
27. De Negri M, Baglietto MG, Battaglia FM, et al. Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. *Brain Dev* 1995;17:330–333.
28. Wilson RB, Eliyan Y, Sankar R, et al. Amantadine: a new treatment for refractory electrical status epilepticus in sleep. *Epilepsy Behav* 2018;84:74–78.
29. Cooper EC, Aldape KD, Abosch A, et al. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. *Proc Natl Acad Sci U S A* 2000;97:4914–4919.
30. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. *Science* 1998;279:403–406.
31. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. *Nat Genet* 1998;18:53–55.
32. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. *Nat Genet* 1998;18:25–29.
33. Weckhuysen S, Ivanovic V, Hendrickx R, et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. *Neurology* 2013;81:1697–1703.
34. Sanders SJ, Campbell AJ, Cottrell JR, et al. Progress in understanding and treating SCN2A-mediated disorders. *Trends Neurosci* 2018;41:442–456.
35. Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. *Epilepsia* 2016;57:2019–2030.
36. Wolff M, Johannesen KM, Hedrich UB, et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. *Brain* 2017;140:1316–1336.
37. Hadley JK, Passmore GM, Tatulian L, et al. Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. *J Neurosci* 2003;23:5012–5019.
38. Kanaumi T, Takashima S, Iwasaki H, et al. Developmental changes in KCNQ2 and KCNQ3 expression in human brain: possible contribution to the age-dependent etiology of benign familial neonatal convulsions. *Brain Dev* 2008;30:362–369.
39. Numis AL, Angriman M, Sullivan JE, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. *Neurology* 2014;82:368–370.
40. van Bon BW, Coe BP, Bernier R, et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. *Mol Psychiatry* 2016;21:126–132.
41. Bernier R, Golzio C, Xiong B, et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell* 2014;158:263–276.
42. Buckley AW, Holmes GL. Epilepsy and autism. *Cold Spring Harb Perspect Med* 2016;6:a022749.